Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Gleevec/Glivec was produced by Novartis.

Novartis pulls EMA application for expanded Tasigna use

Novartis pulls EMA application for expanded Tasigna use molecular response' when treated with the company's Glivec/Gleevec (imatinib).

Niche-busting cancer immunotherapies

Niche-busting cancer immunotherapies Novartis's Glivec represents the first real advance in getting 'under the hood' of cancer at the molecular level. ... By targeting a protein made by a mutated gene, Glivec has allowed chronic myeloid leukaemia (CML) patients to live nearly normal lives

Back to the future

Back to the future Curiously, however, only five of the top 20 best-selling treatments are indicated for cancer: MabThera, Avastin, Herceptin, Glivec ($4.7b) and Revlimid ($4.3bn).

Pharma deals during April 2014

Pharma deals during April 2014 Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and its follow-up Tasigna (blood-cancer); Afinitor (kidney cancer and recently approved for breast cancer);

Uptake challenges for personalised medicines and companion diagnostics

Uptake challenges for personalised medicines and companion diagnostics strategy (eg measuring peripheral blood BCR-ABL transcript levels in patients on Glivec to identify patients likely to achieve better long-term outcome if they are switched early to second-line

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]

Subscribe to our email news alerts


Add my company
Evoke Kyne

Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...

Latest intelligence

Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...